APOE and hyperlipidemia: As such, it can be hypothesized that the null effect of SGC707 treatment on non-fasting plasma lipid levels in apoE knockout mice is related to a relatively minor contribution of hepatic VLDL production to the hyperlipidemia in this specific mouse model.